文献速递炎症性肠病

COVID-19疫苗对炎症性肠病患者Omicron变异株的有效性:退伍军人事务部队列研究

COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2022-11-26

该回顾性队列研究纳入22756例炎症性肠病患者,随访2022年1月Omicron波期间,发现加强针接种与SARS-CoV-2感染风险降低30%相关(HR 0.70,95%CI 0.56-0.88,P=0.002),疫苗有效性25.05%;与COVID-19住院风险降低相关(HR 0.35,95%CI 0.16-0.74,P=0.006),有效性65.06%;与全因死亡率无显著关联。

要点

  • 加强针接种与SARS-CoV-2感染风险降低相关(HR 0.70,95%CI 0.56-0.88,P=0.002),有效性25.05%。
  • 加强针接种与COVID-19住院风险降低相关(HR 0.35,95%CI 0.16-0.74,P=0.006),有效性65.06%。
  • 调整模型中疫苗接种状态与全因死亡率无显著关联。

核心结论

  • 加强针接种状态与较低的SARS-CoV-2感染风险和COVID-19相关住院风险相关。
  • 疫苗有效性低于针对既往变异株所见,且随加强针接种后时间延长而下降。
  • 作者认为炎症性肠病患者,尤其是免疫抑制者,应按美国疾病控制与预防中心建议考虑接种第二剂加强针。

研究设计与样本

  • 回顾性队列研究,使用退伍军人健康管理局中成熟的炎症性肠病队列。
  • 共纳入22756例炎症性肠病患者,其中34.9%已接种加强针。
  • 随访基线炎症性肠病用药患者至2022年1月Omicron COVID-19波期间。
  • 构建调整模型评估疫苗接种和加强针对减少SARS-CoV-2感染、住院和全因死亡的有效性。

主要发现

  • 随访期间622例患者(2.7%)诊断为SARS-CoV-2感染。
  • 调整模型中,加强针状态与SARS-CoV-2感染风险降低30%相关(风险比0.70 vs 未接种状态,95%CI 0.56-0.88,P=0.002),疫苗有效性25.05%。
  • 加强针状态与COVID-19住院风险降低显著相关(风险比0.35,95%CI 0.16-0.74,P=0.006),调整模型中有效性65.06%。
  • 调整模型中疫苗接种状态与全因死亡率无显著关联。

临床怎么用

  • 作者建议炎症性肠病患者,尤其是免疫抑制者,应按美国疾病控制与预防中心建议考虑接种第二剂加强针。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With the advent of the Omicron variant, there are concerns about the efficacy of current vaccinations, especially among immunocompromised/immunosuppressed patients. Our aim was to determine the efficacy of the first booster dose against Omicron. METHODS: This was a retrospective cohort study using a well-established inflammatory bowel disease (IBD) cohort in the Veterans Health Administration. We followed patients on baseline IBD medications through the month of January 2022 during the Omicron COVID-19 wave and created adjusted models for vaccination and boosting effectiveness in reducing SARS-CoV-2 infection, hospitalization, and all-cause mortality. RESULTS: A total of 22,756 patients with IBD were included, of whom 34.9% had received a booster dose. During follow-up, 622 patients (2.7%) were diagnosed with SARS-CoV-2 infection. In adjusted models, booster status was associated with a 30% reduced hazard of SARS-CoV-2 infection (hazard ratio 0.70 vs unvaccinated status, 95% confidence interval 0.56-0.88, P = 0.002), translating to 25.05% effectiveness. Boosted status was also significantly associated with reduced COVID-19 hospitalization (hazard ratio 0.35, 95% confidence interval 0.16-0.74, P = 0.006), demonstrating a 65.06% effectiveness in adjusted models. There was no significant association between vaccination status and all-cause mortality in adjusted models. DISCUSSION: The boosted state was associated with a lower risk of SARS-CoV-2 infections and COVID-19-related hospitalization. Efficacy was lower than what has been seen against previous variants and decreased with prolonged duration from the booster. These findings suggest that patients with IBD, especially those who are immunosuppressed, should consider getting a second booster as per Centers for Disease Control and Prevention recommendations.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Khan N, Mahmud N. COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2022. PMID: 36730187. doi:10.14309/ajg.0000000000002071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。